Brain-on-Chip Neural Repair Models: Mechanisms, Clinical Relevance, and Future Directions

Abstract

Brain-on-chip neural repair models represent a transformative frontier in translational neuroscience, integrating microengineering technologies with neurobiology to create physiologically relevant in vitro systems for studying neural injury and regeneration. This review explores the epidemiology of neural damage, the underlying pathophysiological mechanisms, risk factors, clinical manifestations, and current diagnostic and management modalities. Emphasis is placed on the emergence of brain-on-chip platforms, their mechanistic insights, clinical applications, and alignment with recent guideline recommendations, providing a comprehensive resource for clinicians and medical researchers invested in neuroregenerative medicine.

Introduction

Injury to the central nervous system (CNS) remains a formidable challenge in clinical neurology, owing to the limited capacity for neural regeneration and the complexity of brain tissue architecture. Traditional in vitro and in vivo models have offered invaluable insights but are often constrained by species differences and a lack of physiological fidelity. The advent of brain-on-chip technology a convergence of microfluidics, biomaterials, and stem cell biology has enabled the recreation of key aspects of the human brain microenvironment. These models provide a cutting-edge platform for dissecting neural repair mechanisms, screening novel therapeutics, and personalizing neuroregenerative strategies. This review systematically examines the clinical and research landscape surrounding brain-on-chip neural repair models, underscoring their pivotal role in advancing translational neuroscience.

Epidemiology / Disease Burden

The global burden of neural injury encompasses traumatic brain injury (TBI), stroke, neurodegenerative diseases, and iatrogenic insults, collectively affecting millions annually. The World Health Organization estimates that over 69 million individuals experience TBI each year, with a significant proportion developing chronic sequelae. Stroke remains a leading cause of adult disability, while neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease continue to rise with aging populations. The limitations of CNS repair contribute to persistent morbidity, highlighting the urgent need for improved models that can facilitate the development of effective regenerative therapies.

Pathophysiology

Neural injury initiates a cascade of pathophysiological events, including excitotoxicity, oxidative stress, inflammatory responses, and blood-brain barrier disruption. The microenvironment of the damaged CNS is characterized by gliosis, scar formation, and loss of neuronal connectivity, impeding endogenous repair. Brain-on-chip platforms recapitulate these complex processes by incorporating relevant cell types neurons, astrocytes, microglia, and endothelial cells within anatomically and functionally organized microenvironments. This facilitates mechanistic studies of axonal regeneration, synaptic plasticity, and neurovascular interactions, providing a nuanced understanding of CNS repair dynamics.

Risk Factors

Risk factors for CNS injury and impaired neural repair include advanced age, comorbidities (such as diabetes and hypertension), genetic predispositions, and lifestyle variables (e.g., alcohol misuse, sedentary behavior). Additionally, the presence of chronic neuroinflammation or previous neural insults can exacerbate tissue vulnerability and impair regenerative processes. Brain-on-chip models permit the systematic manipulation of these risk factors, enabling researchers to delineate their individual and synergistic effects on neural repair mechanisms and therapeutic responses.

Clinical Features

Clinical manifestations of neural injury are heterogeneous, encompassing cognitive deficits, motor dysfunction, sensory alterations, and neuropsychiatric symptoms. The severity and spectrum of symptoms depend on the location, extent, and etiology of the damage. Brain-on-chip devices can be tailored to mimic specific regions or circuits of the human brain, allowing for the study of region-specific pathologies and repair mechanisms. This customization enhances the translational relevance of preclinical findings and supports the development of targeted interventions.

Diagnosis

Diagnosis of CNS injury integrates clinical assessment with advanced neuroimaging modalities, including MRI, CT, and PET scans, as well as emerging biomarkers such as neurofilament light chain. While these tools provide structural and functional insights, they are limited in capturing dynamic molecular and cellular events underlying repair. Brain-on-chip systems offer a complementary approach, enabling real-time analysis of cellular responses, electrophysiological activity, and molecular signaling during neural regeneration. This can inform the development of novel diagnostic assays and facilitate patient stratification in clinical trials.

Treatment & Management

Current management of CNS injury is largely supportive, focusing on stabilization, rehabilitation, and symptomatic relief. Pharmacological options remain limited, with few agents demonstrating efficacy in promoting neural repair. Cell-based therapies, neurotrophic factors, and neuromodulation represent areas of active investigation. Brain-on-chip models serve as high-throughput platforms for screening pharmacological agents, optimizing dosing strategies, and predicting therapeutic efficacy and toxicity in a human-relevant context. This accelerates the translation of promising therapies from bench to bedside.

Recent Advances / Emerging Therapies

The past decade has witnessed significant advances in the development of brain-on-chip technologies, including the integration of patient-derived induced pluripotent stem cells (iPSCs), 3D bioprinting of neural circuits, and the incorporation of microelectrode arrays for functional readouts. Emerging therapies evaluated using these platforms include gene editing, exosome-based delivery systems, and combinatorial approaches targeting multiple repair pathways. Early-phase studies demonstrate the potential of these models to predict clinical outcomes more accurately and reduce reliance on animal testing, in line with ethical and regulatory trends.

Guideline Recommendations

Leading neurological and neurorehabilitation societies increasingly advocate for the adoption of advanced in vitro models, such as brain-on-chip systems, in preclinical research and drug development pipelines. Guideline recommendations emphasize the need for physiologically relevant, reproducible, and scalable platforms to bridge the translational gap between laboratory findings and clinical application. Collaborative consortia, including the NIH BRAIN Initiative and Horizon 2020, are actively supporting the standardization and validation of these technologies, ensuring their integration into evidence-based neuroregenerative medicine.

Conclusion

Brain-on-chip neural repair models represent a paradigm shift in neuroscience research and clinical translation, offering unprecedented fidelity in recapitulating the human CNS microenvironment. By enabling detailed mechanistic studies, personalized therapeutic testing, and alignment with regulatory guidelines, these platforms are poised to accelerate the discovery and implementation of effective neural repair strategies. Continued interdisciplinary collaboration, technological refinement, and clinical validation will be essential for realizing the full potential of brain-on-chip systems in advancing patient care and neurological recovery.